ATE453402T1 - Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis - Google Patents

Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis

Info

Publication number
ATE453402T1
ATE453402T1 AT01971584T AT01971584T ATE453402T1 AT E453402 T1 ATE453402 T1 AT E453402T1 AT 01971584 T AT01971584 T AT 01971584T AT 01971584 T AT01971584 T AT 01971584T AT E453402 T1 ATE453402 T1 AT E453402T1
Authority
AT
Austria
Prior art keywords
serp
combination
immunosuppressor
compositions
methods
Prior art date
Application number
AT01971584T
Other languages
English (en)
Inventor
Robert Z Zhong
Alexandra Lucas
Grant D Mcfadden
Original Assignee
Viron Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viron Therapeutics Inc filed Critical Viron Therapeutics Inc
Application granted granted Critical
Publication of ATE453402T1 publication Critical patent/ATE453402T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT01971584T 2000-09-29 2001-09-28 Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis ATE453402T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23693900P 2000-09-29 2000-09-29
PCT/CA2001/001369 WO2002026245A2 (en) 2000-09-29 2001-09-28 Use of serp-1 in combination with an immunosuppressant for influencing inflammatory and immune reactions

Publications (1)

Publication Number Publication Date
ATE453402T1 true ATE453402T1 (de) 2010-01-15

Family

ID=22891637

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01971584T ATE453402T1 (de) 2000-09-29 2001-09-28 Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis

Country Status (8)

Country Link
US (1) US7419670B2 (de)
EP (1) EP1365798B1 (de)
JP (1) JP2004509171A (de)
AT (1) ATE453402T1 (de)
AU (2) AU2001291579B2 (de)
CA (1) CA2423313A1 (de)
DE (1) DE60140960D1 (de)
WO (1) WO2002026245A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60020727T2 (de) 1999-10-27 2006-05-04 Robert London Zhong Zusammensetzung zur vorbeugung und behandlung von transplantatabstossung
AU2001291579B2 (en) 2000-09-29 2006-08-31 Viron Therapeutics Inc. Use of serp- 1 in combination with an immunosuppressant for influencing inflammatory and immune reactions
WO2004039391A1 (en) * 2002-11-01 2004-05-13 Lucas Alexandra R Viral serpin regulation of inflamation
FR2849598B1 (fr) * 2003-01-07 2006-09-22 Merck Sante Sas Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete, par augmentation du nombre de cellules des ilots de langerhans
US7285530B2 (en) 2004-10-21 2007-10-23 Viron Therapeutics, Inc. Use of SERP-1 as an antiplatelet agent
EP2023948A1 (de) * 2006-05-04 2009-02-18 Michel Ovize Verwendung von cyclosporin a oder melle4-cyclosporin zur behandlung von akutem myokardinfarkt
US8251876B2 (en) 2008-04-22 2012-08-28 Hill-Rom Services, Inc. Breathing exercise apparatus
WO2012029061A2 (en) 2010-08-31 2012-03-08 Uri Wormser POLYPEPTIDES DERIVED FROM α-1 ANTITRYPSIN AND METHODS OF USE THEREOF
US9518107B2 (en) 2010-08-31 2016-12-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Pharmaceutical compositions containing polypeptides derived from α-1 antitrypsin and methods of use thereof
US20140050728A1 (en) * 2011-01-28 2014-02-20 Board Of Regents Of The University Of Nebraska Methods and compositions for inhibiting cyclophilin d for the treatment and prevention of obesity and kidney indications
US9180271B2 (en) 2012-03-05 2015-11-10 Hill-Rom Services Pte. Ltd. Respiratory therapy device having standard and oscillatory PEP with nebulizer
US10842763B2 (en) 2015-07-31 2020-11-24 The Johns Hopkins University Methods for cancer and immunotherapy using prodrugs of glutamine analogs
EA034571B1 (ru) 2015-07-31 2020-02-21 Дзе Джонс Хопкинс Юниверсити Пролекарства аналогов глутамина
CN108135875B (zh) 2015-07-31 2021-12-31 约翰霍普金斯大学 用于治疗代谢重编程病症的方法和组合物
US11185534B2 (en) 2017-02-01 2021-11-30 The Johns Hopkins University Prodrugs of glutamine analogs
CN113645986A (zh) * 2019-01-14 2021-11-12 亚利桑那州立大学董事会 丝氨酸蛋白酶抑制剂：serp-1和serp-1rcl衍生肽对微生物群组成的作用及其用途

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206017A (en) 1986-06-03 1993-04-27 Incyte Pharmaceuticals, Inc. Use of protease nexin-I as an antiinflammatory
DE3829523A1 (de) 1988-08-31 1990-03-01 Behringwerke Ag Verwendung von plasminogen-aktivator-inhibitor (pai-2) zur immunsuppression
GB9007971D0 (en) * 1990-04-09 1990-06-06 Imutran Ltd Pharmaceutical formulations
ATE146970T1 (de) 1990-10-16 1997-01-15 John Lezdey Behandlung von entzündungen
WO1992022320A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. C1 inhibitor variants and treating inflammatory response with c1 inhibitor
DE4214215A1 (de) 1992-04-30 1993-11-04 Behringwerke Ag Verwendung von inhibitoren von plasminogenaktivatoren zur behandlung von entzuendungen
US5686409A (en) * 1994-04-08 1997-11-11 Research Corporation Technologies, Inc. Antirestenosis protein
US5624946A (en) * 1994-07-05 1997-04-29 Williams; James Use of leflunomide to control and reverse chronic allograft rejection
US5939525A (en) * 1995-03-27 1999-08-17 Viron Therapeutics, Inc. Methods of treating inflammation and compositions therefor
WO1997010006A1 (en) 1995-09-11 1997-03-20 The Governors Of The University Of Alberta Method for inhibiting cell-mediated killing of target cells
GB9811854D0 (en) * 1998-06-02 1998-07-29 Ciba Geigy Ag Organic compounds
EP0982035B1 (de) 1998-08-18 2004-03-31 Panacea Biotec Limited Zusammensetzung enthalten Cyclsoporin in einem hydrophilen Träger
US20020006901A1 (en) 1999-02-05 2002-01-17 Aldo T. Iacono Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease
AU3729300A (en) 1999-03-10 2000-09-28 American Red Cross Brain-associated inhibitor of tissue-type plasminogen activator
DE60020727T2 (de) * 1999-10-27 2006-05-04 Robert London Zhong Zusammensetzung zur vorbeugung und behandlung von transplantatabstossung
US6428308B1 (en) 1999-11-29 2002-08-06 Honeywell Inc. Electronic fuel convertibility selection
WO2001039790A1 (en) 1999-12-02 2001-06-07 Viron Therapeutics, Inc. Methods of treating inflammation and compositions therefor
AU2001291579B2 (en) 2000-09-29 2006-08-31 Viron Therapeutics Inc. Use of serp- 1 in combination with an immunosuppressant for influencing inflammatory and immune reactions
WO2004039391A1 (en) 2002-11-01 2004-05-13 Lucas Alexandra R Viral serpin regulation of inflamation
US7285530B2 (en) * 2004-10-21 2007-10-23 Viron Therapeutics, Inc. Use of SERP-1 as an antiplatelet agent

Also Published As

Publication number Publication date
JP2004509171A (ja) 2004-03-25
DE60140960D1 (de) 2010-02-11
EP1365798B1 (de) 2009-12-30
AU2001291579B2 (en) 2006-08-31
WO2002026245A3 (en) 2003-10-09
US20040029801A1 (en) 2004-02-12
CA2423313A1 (en) 2002-04-04
AU9157901A (en) 2002-04-08
EP1365798A2 (de) 2003-12-03
WO2002026245A2 (en) 2002-04-04
US7419670B2 (en) 2008-09-02

Similar Documents

Publication Publication Date Title
ATE453402T1 (de) Verwendung von serp-1 in kombination mit einem immunosuppressor zur behandlung von arthritis
ATE328605T1 (de) Verwendung von insulin zur behandlung von knorpelkrankheiten
IL267381A (en) A pharmaceutical preparation containing dextromethorphan and quinidine for the treatment of nervous disorders
ATE309802T1 (de) Verwendung von cyclopamine zur behandlung von psoriasis und anderen hauterkrankungen
DE60037394D1 (de) VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
DE69733132D1 (de) Verwendung von antioxidantien zur behandlung cholestatischer lebererkrankungen
ATE265213T1 (de) Noribogain zur behandlung von schmerzen und drogenabhängigkeit
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
ATE394097T1 (de) Verfahren zur verabreichung von buprenorphin zur behandlung von depression
ATE230609T1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
ATE297739T1 (de) Endothelin-antagonisten zur behandlung von herzversagen
ATE251462T1 (de) Verfahren zur behandlung von narbengewebe
DE69623316D1 (de) Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen
ATE268170T1 (de) Verwendung von bernsteisäure oder deren salze zur behandlung von insulinresistenz
ATE369143T1 (de) Verwendung von ngali nussöl zur behandlung/linderung der arthritisschmerzen und anderer ähnlichen störungen
ATE236633T1 (de) Topische verwendung von loperamid zur behandlung mikrobieller infektionen
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
NO984196D0 (no) Fremgangsmåte for behandling av stoffmisbruk
DE69635282D1 (de) Behandlung der exzessiven aggressivität mit olanzapine
ATE291434T1 (de) Verwendung von angiotensin zur behandlung von krebsmetastasierung
ATE345138T1 (de) Verfahren und zusammensetzungen zur vorbeugung und behandlung von sodbrennen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties